• Explore /
  • Poster
  • / Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).

Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).

Abstract Poster

Authors

Joyce O'Shaughnessy

Joyce O'Shaughnessy

Baylor Charles A. Sammons Cancer Center, US Oncology and Texas Oncology, Dallas, TX

Joyce O'Shaughnessy , Rebecca L. Moroose , Sunil Babu , Kakhaber Baramidze , David Chan , Stuart P. Leitner , Gia Nemsadze , Peter Ordentlich , Christine Quaranto , Michael L. Meyers , Valeria González Graf , Taunya J. Smith , Valerie Bee-Munteanu , Rodrigo Fresco , Dennis J. Slamon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02708680

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1014)

DOI

10.1200/JCO.2020.38.15_suppl.1014

Abstract #

1014

Poster Bd #

99

Abstract Disclosures

Similar Posters

First Author: John Ebben

First Author: Manish R. Patel

First Author: Gabriela Liliana Bravo Montenegro

First Author: Sophie Cousin